Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Timothy Chan
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Gritstone Oncology
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Chan is founder of, has an equity interest in, and serves on the scientific advisory board of Gritstone Oncology. Dr. Chan is co-inventor of intellectual property related to neoantigens for prediction of immunotherapy response; MSK has licensed this technology to Gritstone. The ultimate goal of this research is to find effective neoantigen-directed immunotherapy that will improve survival for patients with recurrent or metastatic salivary gland cancer. The aims of this research intersect with Gritstone's focus on developing tumor-specific cancer immunotherapies to fight multiple cancer types.
Identifying and targeting neoantigens in aggressive salivary carcinomas
Narrative Salivary gland cancers are rare but deadly cancers that have no broadly effective therapies once metastases develop. We seek to identify cancer-specific antigens resulting from genetic alterations (neoantigens) that are shared across salivary gland cancers, to learn whether the effectiveness of current immunotherapy in patients with salivary gland cancers is related to the number of neoantigens in their tumor, and to develop ways of targeting shared neoantigens with immunotherapy. The ultimate goal is effective neoantigen-directed immunotherapy that will improve survival for patients with recurrent or metastatic salivary gland cancer.
Filed on June 26, 2019.
Tell us what you know about Timothy Chan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Timothy Chan filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Timothy Chan | Sloan Kettering Inst Can Research | Conflict of Interest | Gritstone Oncology | $350,000 - $399,999 |
| Timothy Chan | Sloan Kettering Inst Can Research | Conflict of Interest | Personal Genome Diagnostics | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.